



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

Name of Journal:

World Journal of Gastrointestinal Oncology

Manuscript ID:

68061

Manuscript Type:

Minireviews

Dear Editor,

Please find enclosed the resubmitted revised manuscript for the mini review titled: Multimodal treatment in oligometastatic gastric cancer

Manuscript **NO.:** 68061

We have read thoroughly all the reviewer comments with the constructive criticism.

We have taken all comments into consideration, and we answered the questions and revised the text accordingly.

I am herewith attaching the revised manuscript and the point-to-point replies to the reviewers.

Best regards,

Mickael Chevallay

SPECIFIC COMMENTS TO AUTHORS

Well written review. Few changes are required. Minor language corrections are required.
Spelling mistakes need to be checked.

1. Abstract 4th line spelling of Prognostic to be written as prognosis

We corrected this misspell (4th line Abstract)

2. Introduction 2nd para 4th line metastatis spelling mistake- metastatic.

We corrected this misspell

3. Prefer to spell single digit numbers.

We spelled out the single digit numbers.

4. Introduction last but 3 rd line- remove words “inferior to”

We removed this error

5. Section 3 rd para- does not seem to affect operative results- Which operative results are being referred to ? specify.

We specified the post-operative results (post-operative morbidity) that were equal between the two groups (gastrectomy alone versus gastrectomy plus hepatectomy). (Line 10, Page 3)

6. REGATTA trial- as authors mentioned the results of first two years- D1 and D2 have no difference in survival rates and DFS for the first 5 years as in the Dutch trial and MRC trial. So, this D1 resection may not been a criticism here.

We removed this criticism and kept only the two arguments (no resection of the metastatic lesions and no neoadjuvant chemotherapy)

7. Section 3.1, para 1 mention which FLOT TRIAL- I think it is about FLOT-4.

We added this reference (Number 32)

8. The full form of HIPEC is not used in the first go.

We corrected the full form to appears first



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

9. HIPEC recommended for PCI>7-quote reference.

We added the reference from the French group of Giehlen et al (Reference number 48)

10. A note can be added on how the response to therapies are assessed in neoadjuvant setting.

We added the revaluation at the end of the neoadjuvant treatment with CT or PET-Scan with a mention of the RECIST criteria. Line 19 Page 7(Reference number 39)

PEER-REVIEW REPORT Number 2

SPECIFIC COMMENTS TO AUTHORS

In the present study, Dr. Chevallay et al. reviewed multimodal treatment in oligometastatic gastric cancer. Although there is some interesting, there are still some comments for the authors.

1. Except the current treatments, other potential treatment options also should be discussed.

We added several new therapeutic agents developed for metastatic disease but that could have a potential use in oligometastatic disease: Trifluridine/tipiracil (Page 7, Line 8), Trastuzumab deruxtecan (Page 12, Line 14), Ramucirumab (Page 12, Line 29).

2. The combined therapy should be added.

We added the combined therapy with chemo-radiotherapy (page 10) with a meta-analysis of Pang et al.

3. The source of Figure 1 should be mentioned.

The reference of Figure 1 is the reference number 25.

4. In the Figure 2, the character of Randomi is unclear, Please correct it.

We corrected the character to make it clearer.

5. A respective schematic diagram for summary the current therapeutic strategies is necessary. I suggest authors add a figure to illustrate it.



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

We added a figure (number 3) for the multimodal management in case of metastatic gastric cancer. (Page 18)

6. The current obstruction for treating oligometastatic gastric cancer should be further discussed.

We have added a paragraph to explain the arguments against surgical management of oligometastatic disease. ((Page 4 , Line 1))

7. The part for future prospects should be added.

We added three on going clinical trial (with their clinical number) in the reference and the manuscript. (Page 4: SURGIGAST, reference 27 ; Page 9: Radiotherapy, reference 57; Page 14: PD-1 Antibody, reference 76)

8. More new references should be added.

We added 10 new references from the initial list.